With a solid cash reserve of approximately $1.1 billion and an additional $1.0 billion from the PTC518 collaboration, PTC is well-positioned for future growth. Furthermore, the positive alignment ...
NTPC too has a separate power trading arm, NTPC Vidyut Vyapar Nigam Ltd. Both PTC India and its subsidiary PFS have been in ...
Looking forward, PTC Therapeutics has provided a broad revenue guidance range for 2025, indicating potential volatility in expected performance. Additionally, the company’s anticipated R&D and ...
More than two years after its approval in Europe, PTC Therapeutics' gene therapy for rare genetic disorder AADC deficiency will soon be made available to patients in the US. The FDA has approved ...
PTC Therapeutic's Upstaza gene therapy for patients with genetic disorder AADC deficiency has been recommended for approval in the EU, setting up another test of the commercial prospects for ...
PTC Therapeutics, Inc. (NASDAQ: PTCT) today provided an update on the Company's progress and its outlook for 2025. Matthew B. Klein, M.D., Chief Executive Officer of PTC, will discuss these updates at ...
Neil Barua, who took the wheel of Seaport-based PTC Inc. (Nasdaq: PTC) last February, earned $16.4 million in total compensation in 2024, according to the company's federal securities filings ...
BlackRock sold 3,31,263 PTC India shares, or 0.11% stake in the company. The investment manager now holds 11,064,987 shares ...
The annual PTC event provides a strategic springboard to focus on planning, networking and discovering what lies ahead for the digital infrastructure, information and communication technology ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback